Literature DB >> 20057286

The expression of H3K9Ac, H3K14Ac, and H4K20TriMe in epithelial ovarian tumors and the clinical significance.

Li Zhen1, Lin Gui-lan, Yan Ping, Huang Jin, Wang Ya-li.   

Abstract

OBJECTIVE: To study the expression of acetylation of histone H3 Lys9, Lys14 (H3K9Ac, H3K14Ac), and trimethylation of histone H4 Lys20 (H4K20TriMe) in ovarian epithelial tumors and the relation with histological grading and clinical staging.
METHODS: The mean optical density of H3K9Ac, H3K14Ac, and H4K20TriMe of normal ovarian epithelium, ovarian adenomas, ovarian borderline tumors, and ovarian epithelial carcinomas was determined by immunohistochemistry, and the relation with histological grading and clinical staging was analyzed.
RESULTS: As the malignancy of ovarian epithelial tumors increased, the expression of H3K9Ac and H4K20TriMe significantly decreased (P < 0.05). Although the expressing difference of H3K14Ac was without statistical significance in each group (P > 0.05), there were no differences in the expression of H3K9Ac, H3K14Ac, and H4K20TriMe in serous cystadenomas, borderline serous cystadenomas, and mucinous cystadenomas (P > 0.05). Compared with mucinous cystadenocarcinomas, the expression of H3K9Ac and H4K20TriMe in serous cystadenocarcinomas was lower (P < 0.05). Although there was no difference of H3K14Ac expression in serous and mucinous cystadenocarcinomas (P > 0.05), as the histological grade reduced, the expression of H3K9Ac and H4K20TriMe reduced (P < 0.05), and it was lower in the late clinical stage than those in the earlier stage (P < 0.01).
CONCLUSIONS: The decreasing of H3K9Ac and H4K20TriMe is possibly related with the occurrence of epithelial ovarian tumors. The more significant the expression of H3K9Ac and H4K20TriMe was, the lower the histological grading and the later the clinical staging were. H3K9Ac and H4K20TriMe were potential biomarkers for prognosis. H3K14Ac showed no significant relation with the occurrence and development of ovarian tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20057286     DOI: 10.1111/IGC.0b013e3181ae3efa

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

Review 1.  Global histone post-translational modifications and cancer: Biomarkers for diagnosis, prognosis and treatment?

Authors:  Shafqat Ali Khan; Divya Reddy; Sanjay Gupta
Journal:  World J Biol Chem       Date:  2015-11-26

2.  Wolf-Hirschhorn Syndrome Candidate 1 (whsc1) Functions as a Tumor Suppressor by Governing Cell Differentiation.

Authors:  Chuan Yu; Xiaomin Yao; Linjie Zhao; Ping Wang; Qian Zhang; Chengjian Zhao; Shaohua Yao; Yuquan Wei
Journal:  Neoplasia       Date:  2017-06-24       Impact factor: 5.715

Review 3.  Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy.

Authors:  Donglu Wu; Ye Qiu; Yunshuang Jiao; Zhidong Qiu; Da Liu
Journal:  Front Oncol       Date:  2020-11-11       Impact factor: 6.244

4.  The role of epigenetics in resistance to Cisplatin chemotherapy in lung cancer.

Authors:  Kenneth J O'Byrne; Martin P Barr; Steven G Gray
Journal:  Cancers (Basel)       Date:  2011-03-17       Impact factor: 6.639

5.  HISTome2: a database of histone proteins, modifiers for multiple organisms and epidrugs.

Authors:  Sanket G Shah; Tushar Mandloi; Pooja Kunte; Abhiram Natu; Mudasir Rashid; Divya Reddy; Nikhil Gadewal; Sanjay Gupta
Journal:  Epigenetics Chromatin       Date:  2020-08-03       Impact factor: 4.954

Review 6.  Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention.

Authors:  Dusan Ruzic; Nemanja Djoković; Tatjana Srdić-Rajić; Cesar Echeverria; Katarina Nikolic; Juan F Santibanez
Journal:  Pharmaceutics       Date:  2022-01-16       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.